Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
ENTITY
SMARTSCORE: 3.6/5
3SBio Inc (1530 HK)
Watchlist
Contact IR
123
Analysis
Health Care
•
China
3SBio, Inc. is a biotechnology company located in China. The Company focuses on mammalian cell-based biopharmaceuticals in the biotechnology industry. 3SBio also develops, manufactures and markets biopharmaceutical products globally.
more
Watchlist
Contact IR
All
Insights
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bearish
•
Quantitative Analysis
•
20 Jul 2019 03:52
Hong Kong Short Reporting - Insights from 12 July Data
We analyse the latest SFC data released last evening on short position reporting in Hong Kong for the week ended 12 July.Total short notional in...
Brian Freitas
Follow
500 Views
Share
bearish
•
Sinomab Bioscience Ltd
•
19 Jul 2019 03:28
SinoMab (中国抗体): Pipeline Concentrated on Autoimmune Therapy
SinoMab, the first Hong Kong-headquartered biotech company coming to list on the SEHK, plans to raise USD100 to 200 million. In this insight, we...
Ke Yan, CFA, FRM
Follow
763 Views
Share
bullish
•
Hansoh Pharmaceutical Group
•
02 Jun 2019 20:21
Hansoh Pharma IPO: Valuation Reasonable for the Trade-Offs
Hansoh Pharmaceutical (3692 HK) claims to be one of the few R&D driven Chinese pharmaceutical companies. It announced its IPO price range of...
Arun George
Follow
793 Views
Share
bullish
•
Hansoh Pharmaceutical Group
•
23 May 2019 01:44
Hansoh Pharma (翰森制药) IPO: Thoughts on Valuation
Hansoh Pharma has started pre-marketing its IPO to raise USD 1bn in its IPO. In our previous insights, we covered the company's major products and...
Ke Yan, CFA, FRM
Follow
855 Views
Share
bearish
•
MabPharm
•
17 May 2019 07:58
MabPharm (迈博医药) IPO: Fairly Valued and Lacks Biotech Investors
MabPharm, a biotech company backed by CDH Investment, launched book building today. In our previous insights, we have discussed the company's...
Ke Yan, CFA, FRM
Follow
674 Views
Share
First
Previous
14
15
16
17
18
19
20
Next
Last
For Institutional Investors and Financial Services
For Corporate IR and Strategy
For Private Wealth Intermediaries
Pricing
Who We Are
Careers
FAQs
Research Provider Solutions
Syndicate your Publications
Compliance
Terms of Use
Privacy Policy
Press Kit
RSS Feeds
Request a Free Trial
Avail a Transition Account
Guest Posts on Smartkarma
Other Enquiries
Join TL;DR Community
Free Weekly Newsletters
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.54.9
x